PI3K/Akt signalling pathway and cancer

Fruman, 1998, Phosphoinositide kinases, Annu. Rev. Biochem., 67, 481, 10.1146/annurev.biochem.67.1.481 Hunter, 2000, Signaling–2000 and beyond, Cell, 100, 113, 10.1016/S0092-8674(00)81688-8 Pawson, 2000, Protein–protein interactions define specificity in signal transduction, Genes. Dev., 14, 1027, 10.1101/gad.14.9.1027 Staal, 1987, Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma, Proc. Natl. Acad. Sci. USA, 84, 5034, 10.1073/pnas.84.14.5034 Jones, 1991, Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily, Proc. Natl. Acad. Sci. USA, 88, 4171, 10.1073/pnas.88.10.4171 Coffer, 1991, Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families, Eur. J. Biochem., 201, 475, 10.1111/j.1432-1033.1991.tb16305.x Bellacosa, 1991, A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region, Science, 254, 274, 10.1126/science.1833819 Murthy, 2000, Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization, Cytogenet. Cell Genet., 88, 38, 10.1159/000015481 Jones, 1991, Molecular cloning of a second form of rac protein kinase, Cell Regul., 2, 1001, 10.1091/mbc.2.12.1001 Andjelkovic, 1995, Developmental regulation of expression and activity of multiple forms of the Drosophila RAC protein kinase, J. Biol. Chem., 270, 4066, 10.1074/jbc.270.8.4066 Alessi, 1996, Mechanism of activation of protein kinase B by insulin and IGF-1, EMBO J., 15, 6541, 10.1002/j.1460-2075.1996.tb01045.x Blume-Jensen, 2001, Oncogenic kinase signalling, Nature, 411, 355, 10.1038/35077225 Lynch, 1999, Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism, Oncogene, 18, 8024, 10.1038/sj.onc.1203258 Persad, 2001, Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343, J. Biol. Chem., 276, 27462, 10.1074/jbc.M102940200 Delcommenne, 1998, Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase, Proc. Natl. Acad. Sci. USA, 95, 11211, 10.1073/pnas.95.19.11211 Meier, 1999, Regulation of protein kinase B, J. Recept. Signal Transduct. Res., 19, 121, 10.3109/10799899909036639 Testa, 2001, AKT plays a central role in tumorigenesis, Proc. Natl. Acad. Sci. USA, 98, 10983, 10.1073/pnas.211430998 Chen, 2001, Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer, Oncogene, 20, 6073, 10.1038/sj.onc.1204736 Kandasamy, 2002, Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells, Cancer Res., 62, 4929 Wang, 2002, Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells, J. Biol. Chem., 277, 36602, 10.1074/jbc.M206306200 Yuan, 2002, PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway, Oncogene, 21, 319, 10.1038/sj.onc.1205054 Diehl, 1998, Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization, Genes Dev., 12, 3499, 10.1101/gad.12.22.3499 Zhou, 2001, Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells, Nat. Cell Biol., 3, 245, 10.1038/35060032 Viglietto, 2002, Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer, Nat. Med., 8, 1136, 10.1038/nm762 Liang, 2002, PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest, Nat. Med., 8, 1153, 10.1038/nm761 Shin, 2002, PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization, Nat. Med., 8, 1145, 10.1038/nm759 Sherr, 2000, The ARF/p53 pathway, Curr. Opin. Genet. Dev., 10, 94, 10.1016/S0959-437X(99)00038-6 Tee, 2002, Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling, Proc. Natl. Acad. Sci. USA, 99, 13571, 10.1073/pnas.202476899 Potter, 2002, Akt regulates growth by directly phosphorylating Tsc2, Nat. Cell Biol., 4, 658, 10.1038/ncb840 Manning, 2002, Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway, Mol. Cell, 10, 151, 10.1016/S1097-2765(02)00568-3 Inoki, 2002, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling, Nat. Cell Biol., 4, 648, 10.1038/ncb839 Dan, 2002, Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin, J. Biol. Chem., 277, 35364, 10.1074/jbc.M205838200 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Shayesteh, 1999, PIK3CA is implicated as an oncogene in ovarian cancer, Nat. Genet., 21, 99, 10.1038/5042 Ma, 2000, PIK3CA as an oncogene in cervical cancer, Oncogene, 19, 2739, 10.1038/sj.onc.1203597 Bellacosa, 1995, Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas, Int. J. Cancer, 64, 280, 10.1002/ijc.2910640412 Cheng, 1996, Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA, Proc. Natl. Acad. Sci. USA, 93, 3636, 10.1073/pnas.93.8.3636 Ruggeri, 1998, Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas, Mol. Carcinog., 21, 81, 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R Rodriguez-Viciana, 1997, Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras, Cell, 89, 457, 10.1016/S0092-8674(00)80226-3 Kauffmann-Zeh, 1997, Suppression of c-Myc-induced apoptosis by Ras signalling through PI (3)K and PKB, Nature, 385, 544, 10.1038/385544a0 Harari, 2000, Molecular mechanisms underlying ErbB2/HER2 action in breast cancer, Oncogene, 19, 6102, 10.1038/sj.onc.1203973 Olayioye, 2000, The ErbB signaling network: receptor heterodimerization in development and cancer, EMBO J., 19, 3159, 10.1093/emboj/19.13.3159 Zhou, 2000, HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway, J. Biol. Chem., 275, 8027, 10.1074/jbc.275.11.8027 Nicholson, 2002, The protein kinase B/Akt signalling pathway in human malignancy, Cell Signal., 14, 381, 10.1016/S0898-6568(01)00271-6 Weng, 1999, PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death, Cancer Res., 59, 5808 Lu, 1999, The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells, Oncogene, 18, 7034, 10.1038/sj.onc.1203183 Simpson, 2001, PTEN: life as a tumor suppressor, Exp. Cell Res., 264, 29, 10.1006/excr.2000.5130 O'Gorman, 2001, Molecular signals in anti-apoptotic survival pathways, Leukemia, 15, 21, 10.1038/sj.leu.2401998 Bacus, 2002, AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival, Oncogene, 21, 3532, 10.1038/sj.onc.1205438 Knuefermann, 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells, Oncogene, 22, 3205, 10.1038/sj.onc.1206394 Page, 2000, Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis, Anticancer Res., 20, 407 Hu, 2002, Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models, Cancer Res., 62, 1087 Aoudjit, 2001, Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells, Oncogene, 20, 4995, 10.1038/sj.onc.1204554 Brognard, 2001, Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation, Cancer Res., 61, 3986 Schmidt, 2002, A novel form of constitutively active farnesylated Akt1 prevents mammary epithelial cells from anoikis and suppresses chemotherapy-induced apoptosis, Br. J. Cancer, 87, 924, 10.1038/sj.bjc.6600566 Ng, 2000, Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells, Cancer Res., 60, 5451 Tanaka, 2000, MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells, Oncogene, 19, 5406, 10.1038/sj.onc.1203918 Roy, 2002, AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis, Carcinogenesis, 23, 201, 10.1093/carcin/23.1.201 Itoh, 2002, Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma, Cancer, 94, 3127, 10.1002/cncr.10591 Gupta, 2002, Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction, Clin. Cancer Res., 8, 885 Fabbro, 2002, Protein tyrosine kinase inhibitors: new treatment modalities?, Curr. Opin. Pharmacol., 2, 374, 10.1016/S1471-4892(02)00179-0 Wakeling, 2002, Epidermal growth factor receptor tyrosine kinase inhibitors, Curr. Opin. Pharmacol., 2, 382, 10.1016/S1471-4892(02)00183-2 de Bono, 2002, The ErbB receptor family: a therapeutic target for cancer, Trends Mol. Med., 8, S19, 10.1016/S1471-4914(02)02306-7 Herbst, 2002, Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy, Cancer, 94, 1593, 10.1002/cncr.10372 Sirotnak, 2000, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, Clin. Cancer Res., 6, 4885 Pollack, 1999, Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice, J. Pharmacol. Exp. Ther., 291, 739 Lynch, 2002, Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment, Semin. Oncol., 29, 47, 10.1053/sonc.2002.31522 Yang, 2001, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Crit. Rev. Oncol. Hematol., 38, 17, 10.1016/S1040-8428(00)00134-7 Hambek, 2001, Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy, Cancer Res., 61, 1045 Herbst, 2002, ZD1839: targeting the epidermal growth factor receptor in cancer therapy, Expert. Opin. Investig. Drugs, 11, 837, 10.1517/13543784.11.6.837 Hidalgo, 2001, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J. Clin. Oncol., 19, 3267, 10.1200/JCO.2001.19.13.3267 Robert, 2001, Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer, J. Clin. Oncol., 19, 3234, 10.1200/JCO.2001.19.13.3234 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101 Ohkanda, 2002, Inhibitors of protein farnesyltransferase as novel anticancer agents, Curr. Top. Med. Chem., 2, 303, 10.2174/1568026023394281 Singh, 2002, Current progress on farnesyl protein transferase inhibitors, Curr. Opin. Drug Discov. Dev., 5, 225 Crooke, 2000, Potential roles of antisense technology in cancer chemotherapy, Oncogene, 19, 6651, 10.1038/sj.onc.1204093 Mukhopadhyay, 1991, Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA, Cancer Res., 51, 1744 Chen, 1996, Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts, J. Biol. Chem., 271, 28259, 10.1074/jbc.271.45.28259 Powis, 1994, Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase, Cancer Res., 54, 2419 Schultz, 1995, In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin, Anticancer Res., 15, 1135 Ng, 2001, Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice, Clin. Cancer Res., 7, 3269 Lemke, 1999, Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase, Cancer Chemother. Pharmacol., 44, 491, 10.1007/s002800051123 Rosenzweig, 1997, Radiosensitization of human tumor cells by the phosphatidylinositol-3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay, Clin. Cancer Res., 3, 1149 Sarkaria, 1998, Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin, Cancer Res., 58, 4375 Kim, 2000, Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin, Leuk. Res., 24, 917, 10.1016/S0145-2126(00)00061-8 Wang, 2002, Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3′-kinase inhibition in the KM20 human colon cancer cell line, Clin. Cancer Res., 8, 1940 Casagrande, 1998, G1 phase arrest by the phosphatidylinositol 3-kinase inhibitor LY 294002 is correlated to up-regulation of p27Kip1 and inhibition of G1 CDKs in choroidal melanoma cells, FEBS Lett., 422, 385, 10.1016/S0014-5793(98)00043-X Hu, 2000, In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002), Clin. Cancer Res., 6, 880 Semba, 2002, The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells, Clin. Cancer Res., 8, 1957 Clark, 2002, Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells, Mol. Cancer Ther., 1, 707 Douros, 1981, New antitumor substances of natural origin, Cancer Treat. Rev., 8, 63, 10.1016/S0305-7372(81)80006-0 Eng, 1984, Activity of rapamycin (AY-22,989) against transplanted tumors, J. Antibiot. (Tokyo), 37, 1231, 10.7164/antibiotics.37.1231 Muthukkumar, 1995, Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells, Transplantation, 60, 264, 10.1097/00007890-199508000-00010 Seufferlein, 1996, Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells, Cancer Res., 56, 3895 Hosoi, 1998, Studies on the mechanism of resistance to rapamycin in human cancer cells, Mol. Pharmacol., 54, 815, 10.1124/mol.54.5.815 Hosoi, 1999, Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells, Cancer Res., 59, 886 Grewe, 1999, Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells, Cancer Res., 59, 3581 Majewski, 2000, The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders, Proc. Natl. Acad. Sci. USA, 97, 4285, 10.1073/pnas.080068597 Dudkin, 2001, Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition, Clin. Cancer Res., 7, 1758 Shi, 1995, Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro, Cancer Res., 55, 1982 Gibbons, 1999, The effect of CCI-779, a novel macrolide anti-tumor agent, on the growth of human tumor cells in vitro and in nude mouse xenografts in vivo, Proc. Am. Assoc. Cancer Res., 40, 2000 Geoerger, 2001, Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy, Cancer Res., 61, 1527 Hidalgo, 2000, Phase I and pharmacological study of CCI-779, a cell cycle inhibitor, Clin. Cancer Res. (Suppl), 6, 413 Hidalgo, 2000, CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study, Proc. Am. Soc. Clin. Oncol., 19, 726 Raymond, 2000, CCI-779, an ester analogue of rapamycin that interacts with PTEN/PI3 kinase pathways: a phase I study utilizing a weekly intravenous schedule, Clin. Cancer Res. (Suppl), 6, 414 Raymond, 2000, CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule, Proc. Am. Soc. Clin. Oncol., 19, 728 Chan, 2002, First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy, Proc. Am. Soc. Clin. Oncol., 21, 175 Atkins, 2002, A randomized double-blind phase 2 study of intravenous CCI-779 administered weekly to patients with advanced renal cell carcinoma, Proc. Am. Soc. Clin. Oncol., 21, 36